Dr. Joseph Francisco is a preclinical development professional with more than 25 years of experience in all phases of drug development, from early discovery through preclinical development. He has broad expertise in small-molecule drugs and biotechnology-derived products, with an emphasis on protein-based therapeutics. This body of knowledge extends to peptide and protein therapeutics, with an emphasis on monoclonal antibodies. He has an expert-level understanding of the strategic and tactical aspects of successful preclinical drug development programs, including program design, execution, and management. He is also intimately familiar with regulatory (FDA and ICH) expectations for preclinical safety assessment.
Prior to joining ToxStrategies, Dr. Francisco held senior-level positions in contract research organizations (CROs) and biopharma companies, and he worked as an independent consultant. He holds a Ph.D. in Chemical Engineering, has participated on teams awarded five U.S. patents, and is an author on over 20 publications in the peer-reviewed literature.